Bard drug eluting ballon lutonix 0.035 AV 8x60mm 75cm

Lutonix Ballon

Maximized Effectiveness Proven Safety.
All sizes 5F sheath profile compatible.
Zero preclinical evidence of downstream necrosis at 90 days*.
GeoAlign Marking System.
Indicated for de novo, restenotic, and in-stent restenotic lesion.

Measurable Clinical Outcomes in AV Access.
At 6 months, the Lutonix 035 DCB demonstrated 71.4% TLPP in the Lutonix AV IDE Clinical Trial.
At 24 months, patients who were treated with a Lutonix 035 DCB went an average of 322 days before needing a reintervention compared to 207 days when treated with a PTA alone.
In the Lutonix DCB AV Global Registry, the Lutonix 035 DCB demonstrated 78.1% TLPP in native fistula, and 73.9% TLPP in native and synthetic (graft) access types, combined, at 6 months.